Multiple experiments have demonstrated that enhancing the intracellular GLUT4 content and promoting its translocation contribute to improving peripheral glucose utilization and provide new ideas for the treatment of T2DM, with the potential to explore GLUT4 as a therapeutic target. This evidence concerns the gene SLC2A4 and type 2 diabetes mellitus.